Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism

ConclusionsSNP rs3803662 (TOX3/TNRC9) is an independent prognostic factor for breast cancer in Henan Han Population. ER ‐TOX3/TNRC9 is the best possible pathway involved in the pathogenesis of breast cancer.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Publication date: Available online 11 November 2019Source: International Journal of PharmaceuticsAuthor(s): Mahsa Shahriari, Seyed Mohammad Taghdisi, Khalil Abnous, Mohammad Ramezani, Mona AlibolandiAbstractIn the current research, the synthesis of polysaccharide-based polymersomes for targeted delivery of doxorubicin is reported. To this aim, doxorubicin was encapsulated in aqueous compartment of hyaluronan-polycaprolactone polymersomes via nanoprecipitation method. Then the therapeutic index of the prepared formulation was studied in metastatic breast cancer model in vitro and in vivo.The size of obtained polymersomes wa...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
ConclusionThe effects of PLB in endocrine-resistant breast cancer cells is dependent on NQO1’s activity.Graphical Abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
This study aims to determine if a disparity in BR utilization exists in women from Appalachia Kentucky. Methods A retrospective, population-based cohort study was conducted from January 1, 2006, to December 31, 2015. The Kentucky Cancer Registry was queried to identify population-level data for female patients diagnosed with breast cancer and treated with mastectomy. A multivariate logistic regression model controlling for patient, disease, and treatment characteristics was constructed to predict the likelihood of BR. Results Bivariate testing showed differences (P
Source: Annals of Plastic Surgery - Category: Cosmetic Surgery Tags: Breast Surgery Source Type: research
Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Jessica L. Hopkins, Lee ZouIn this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Conclusion: Taken together, AFPE that acts at a low micromolar range against breast cancer cells may be considered as a promising candidate for anticancer therapy.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Ruiz Juan Antonio Marchal María Isabel Núñez Breast cancer is the most common cancer in women. Radiotherapy (RT) is one of the mainstay treatments for cancer but in some cases is not effective. Cancer stem cells (CSCs) within the tumor can be responsible for recurrence and metastasis after RT. Matrix metalloproteases (MMPs), regulated mainly by tissue inhibitors of metalloproteinases (TIMPs) and histone deacetylases (HDACs), may also contribute to tumor development by modifying its activity after RT. The aim of this work was to study the effects of RT on the expression of MMPs, TIMPs and HDACs ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPancytopenia is a rare complication among patients with breast cancer. Here, we report a case of pancytopenia due to massive bone marrow carcinomatosis (BMC) developed after local radiotherapy following to mastectomy. A 48-year-old woman with locally advanced breast cancer underwent mastectomy and axillary lymph node dissection. During adjuvant chemotherapy, rapidly growing supraclavicular lymph node metastasis was noted, so chemotherapy was discontinued and local radiotherapy was performed. There was no myelosuppression or systemic metastases prior to radiotherapy, but 2 weeks after the completion of radiotherapy,...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Cell Death &Disease, Published online: 12 November 2019; doi:10.1038/s41419-019-2096-xCorrection: miR-29a contributes to breast cancer cells epithelial–mesenchymal transition, migration, and invasion via downregulating histone H4K20 trimethylation through directly targeting SUV420H2
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
The US Food and Drug Administration (FDA) ’s Centre for Devices and Radiological Health has designated a medical invention by a Bengaluru-based scientist as a “breakthrough device” in liver, pancreatic and breast cancer treatment.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers and is gaining increasing interest as target for novel therapeutic strategies. In sharp contrast with other types of cancer, the importance of RAS in breast tumorigenesis has long been undermined by the low frequency of its oncogenic mutation in human breast lesions. Nevertheless, a wealth of studies over the last years have revealed how the engagement of RAS function might be mandatory downstream varied oncogenic alterations for the progression, metastatic dissemination, and therapy resistance in breast cancers. We review ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Molecular Biology | Study